13F-HR filed by QIMING U.S. VENTURES MANAGEMENT, LLC
QIMING U.S. VENTURES MANAGEMENT, LLC filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-01-28, with 6 holding rows worth $51,146,718.
- Accession
- 0001104659-25-006699
- Filer
- CIK 1909617
- Filed
- 2025-01-28
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2024
A holdings report, 6 entries on the cover page, a total value of $51,146,718 stated on the cover page (in dollars after the unit check, H1), rows summing to $51,146,718 with VALUE read as dollars as filed, 13F file number 028-22101. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| JASPER THERAPEUTICS INC | 471871202 | COM NEW | 928,964 | $19,861,250 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 741,691 | $15,041,493 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 368,085 | $14,012,996 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 412,225 | $902,773 | dollars as filed | |
| HILLEVAX INC | 43157M102 | COM | 372,615 | $771,313 | dollars as filed | |
| KEZAR LIFE SCIENCES INC | 49372L209 | COM NEW | 82,871 | $556,893 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-25-006699 | this filing | 2025-01-28 | acceptance time not in the bulk data set |